Nutriband Inc is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The Company's lead product is its patented AVERSA Transdermal Abuse Deterrent Technology which incorporates aversive agents to prevent the Abuse, diVERsion, miSuse and Accidental exposure of drugs with abuse potential, specifically opioids. This technology can be added to virtually any patch on the market today. The majority of the revenue is currently generated from contract manufacturing and Clinical development however AVERSA Fentanyl, the Company's first product candidate, has been independently estimated by a leading healthcare consulting firm to reach peak annual sales of $85-200 M following a thorough market opportunity assessment.
To commemorate the dual listing, this issuer is giving away free digital collectibles to all current and prospective shareholders. The issuer will announce the claim code on listing day. Then do the following: